A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis
Latest Information Update: 07 Nov 2021
At a glance
- Drugs BIIB 023 (Primary) ; Corticosteroid; Mycophenolate mofetil
- Indications Lupus nephritis
- Focus Therapeutic Use
- Acronyms ATLAS
- Sponsors Biogen
- 12 Jul 2016 This trial was completed in Germany (end date: 28 Dec 2015).
- 13 Apr 2016 This trial is completed in Belgium and Hungary ( end date: 28 Dec 2015).
- 26 Oct 2015 Planned End Date changed from 1 Mar 2017 to 1 Dec 2015 as reported by ClinicalTrials.gov.